Seeking Alpha


Send Message
View as an RSS Feed
View jjjorgen's Comments BY TICKER:
Latest comments  |  Highest rated
  • Analysts Are Lining Up Behind This Undervalued And Fast Growing Biotech [View article]
    The fact is Arnold, you are shorting the company, and have done very little due diligence. Good Luck with that!
    Aug 6, 2012. 06:49 PM | 1 Like Like |Link to Comment
  • Amarin Path Clearer After FDA Approval [View article]
    $25/shr in a buyout would be alright with me. 4th quarter by my projections.
    Jul 31, 2012. 10:02 AM | 1 Like Like |Link to Comment
  • Reassessing And Continuing To Monitor Portfolios For Success [View article]
    Skywola, glad to have you aboard on QCOR. Interesting on the trailing stop buy, as we discussed earier. I need to try that on my next purchase! I also purchased some additional shares today. No matter what the stock does now, I'm fully vested in it. Looking forward to a $10 swing in the right direction.
    Best of Luck!
    Jul 30, 2012. 04:13 PM | 1 Like Like |Link to Comment
  • Zalicus: History Tells Us It's Time To Buy [View article]
    Great article, Looking forward to August!
    Jul 26, 2012. 02:57 PM | 1 Like Like |Link to Comment
  • 5 Momentum Stocks With Pullbacks That Could Be Your Opportunity [View article]
    Questcor is acting a little better today. Still 25% down from where it should be, all things considered. I'm very heavily invested now in QCOR, and I took yesterday's opportunity to add to my position. Us longs should be well rewarded by year-end.
    Jul 26, 2012. 01:40 PM | 1 Like Like |Link to Comment
  • Questcor (QCOR): Q2 EPS of $0.69 beats by $0.06. Revenue of $112.5M beats by $3.5M. (PR)  [View news story]
    Weaker than expected sales??? I think not! Every quarter will vary in some way. But earnings do continue to rapidly rise. 19 indications for use? Can I hear "Opportunity Knocking"? Buying all I can.

    One little blurb from Motley Fool, FWIW:

    So what: It's all about the details of the earnings report. Revenue rose 144.6% from a year ago to $112.5 million, topping estimates, and adjusted earnings per share were $0.69, six cents above estimates.

    But the problem today is the number of rebated prescriptions of Acthar, the company's $23,000-per-vial drug. One estimate from ThinkEquity estimated that 94 MS prescriptions were rebated for a total of 1,167 including paid, but the actual number was 41 for a total of 1,151 total prescriptions. The trend for nephritic syndrome was similarly disappointing.

    Now what: I wouldn't be too worried about the rebate miss, the company has been increasing paid prescriptions at a rapid rate, and both the top and bottom lines were better than expected. Shares now trade at 10 times forward earnings, and if current trends continue, that could be a great deal for investors. Investors can often freak out about small details in earnings reports, but I think the overall picture looks strong, and shares cam move higher from here.
    Jul 25, 2012. 06:38 PM | 1 Like Like |Link to Comment
  • 3 Internal Signs Of Antares On The Move [View article]
    I see everyone is now drinking the Kool-Aid!
    Jul 9, 2012. 10:04 AM | 1 Like Like |Link to Comment
  • Spectrum Pharmaceuticals Reached 10-Year Highs But Has At Least 20% Upside In The Immediate Future [View article]
    Hey Brian,
    See tonight's news?? This is just getting plain ridiculous for Allos! What the heck is going here??? Have you ever seen multiple extensions to complete a sale like Spectrum is going through?
    And now we are told the European part of the transaction is a no-go! I think on Monday some of these wonderful gains start to go by the way-side! Don't you just love how Spectrum spits out this news on a Friday night! Fishy, but with the amount of shares short, can't blame them.
    Jul 6, 2012. 07:39 PM | 1 Like Like |Link to Comment
  • Focus On Perifosine May Shift For AEterna Zentaris Investors [View article]
    They have 6 months to get their share price above $1/shr. If showing efforts to increase pps, they can request 6 months of extension. What else would you like to know, Happy? Are you familiar Nasdaq De-listing rules?
    May 30, 2012. 06:24 PM | 1 Like Like |Link to Comment
  • GT Advanced Technologies (GTAT): FQ4 EPS of $0.69 misses by $0.02. Revenue of $354M (+30.3% Y/Y) misses by $39M. (PR)  [View news story]
    Agreed. It was as good as we could expect, if not better. Love the backlog, good till middle CY 2013. No huge negative surprise, like shorts were expecting. BUT, I'm sure they will beat their drums and tell people GTAT is going out of business. Conference call tomorrow morning will be interesting.
    May 16, 2012. 04:47 PM | 1 Like Like |Link to Comment
  • 6 Small Cap Technology Stocks With Sound Earnings, Buy Ratings [View article]
    It's in my retirement IRA. It can stay awhile, with no loss of sleep from me. Can't imagine this not doubling over the next couple years.
    May 12, 2012. 09:38 AM | 1 Like Like |Link to Comment
  • Cramer's Lightning Round - Don't Worry About Duke (4/27/12) [View article]
    Thanks Cramer, now I know to add to my position! You're wrong, more than your right. Biotechs~ You don't have a clue!
    Apr 30, 2012. 09:56 AM | 1 Like Like |Link to Comment
  • Stocks Worth Buying Prior To Earnings: Week 4 [View article]
    Wow, Byte, you spent a lot of time to figure that out? I buy and sell quite frequently myself. I own 19,000 shares of SPPI currently, but I've been in and out of the stock more than once. Brian may have sold and bought shares between February and now, don't ya think? I know I have! Either way, I'm happy to see he owns shares, better chance of making money than being short right now!
    Apr 27, 2012. 05:31 PM | 1 Like Like |Link to Comment
  • Keryx Will Tank Without The Success Of Zerenex [View article]
    Not a good article. AEZS-108 and 130 are owned by AEterna Zentaris. There is no relation to success or failure of Keryx with these two drugs. But AEterna's future success is dependent on them. Don't even mention Spectrum (SPPI), as you mention one small failure, but forgo mentioning all of their positives, including a low PPS. Read some other SA articles there.
    Apr 20, 2012. 09:09 AM | 1 Like Like |Link to Comment
  • Spectrum Could Sink On Aqaziquone Failure [View article]
    Alright, I'm sure you're playing with me here. Ha Ha. But here's the announcement for you anyway!
    Apr 18, 2012. 08:56 PM | 1 Like Like |Link to Comment